Clinical Trials

42 enrolled

Adenocarcinoma of Lung, Lung Neoplasms

NCT06058377 2026-05-27

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

3,680 enrolled

Anatomic Stage II Breast Cancer AJCC v8

NCT06498635 2026-05-27

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

306 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06694454 2026-05-27

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

60 enrolled

Pathologic Complete Response, Carcinoma, Non-Small-Cell Lung

NCT06274879 2026-05-26

Ablatio

36 enrolled

Bile Duct Neoplasms

NCT05061550 2026-05-22

NeoCOAST-2

630 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06050252 2026-05-22

Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine and Cisplatin) at Improving Outcomes for High-Risk Resectable Liver Cancer Before Surgery

27 enrolled

Resectable Intrahepatic Cholangiocarcinoma

NCT06287775 2026-05-22

Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer

45 enrolled

Lung Neoplasms

NCT06551142 2026-05-22

PanTumor-101

845 enrolled

Tumor-Agnostic

Neoplasms

NCT06954480 2026-05-22

DIAMOND

140 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07005128 2026-05-22

DeLLphi-312

330 enrolled

Small Cell Lung Carcinoma

NCT07531095 2026-05-22

DeLLphi-313

160 enrolled

Small Cell Lung Carcinoma

NCT06992609 2026-05-20

ALBORAN

70 enrolled

Small Cell Lung Carcinoma

NCT06890598 2026-05-19

SUNRAY-02

700 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05211895 2026-05-18

PACIFIC-8

860 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05255653 2026-05-15

RAINBO

Phase 2/3 Recruiting

1,615 enrolled

Gynecologic

Endometrial Neoplasms

NCT07391670 2026-05-15

IMFINZI-subQ

40 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Small Cell Lung Carcinoma

NCT06467357 2026-05-14

DESTINY-BTC01

620 enrolled

Biliary Tract Neoplasms

NCT06591650 2026-05-14

GCND

GastrointestinalGenitourinary

33 enrolled

Gallbladder Cancer Unresectable

NCT07361497 2026-05-14

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

850 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03606967 2026-05-13

Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

70 enrolled

Triple Negative Breast Neoplasms

NCT03907475 2026-05-13

Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial

115 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT04379596 2026-05-13

DG-03

450 enrolled

Adenocarcinoma, Carcinoma, Esophageal Neoplasms, Stomach Neoplasms

NCT04628767 2026-05-13

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

Phase 2/3 Recruiting

249 enrolled

Genitourinary

Renal Pelvis and Ureter Urothelial Carcinoma

NCT05411094 2026-05-13

Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer

18 enrolled

Pancreatic Neoplasms

NCT06058663 2026-05-13

Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma

16 enrolled

Cholangiocarcinoma

NCT07012798 2026-05-13

FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of Potentially Resectable Locally Advanced Hepatocellular Carcinoma

30 enrolled

Carcinoma, Hepatocellular

NCT04918186 2026-05-12

IPROC

60 enrolled

Gynecologic

Ovarian Neoplasms

NCT06282575 2026-05-11

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

286 enrolled

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT06667908 2026-05-11

CONVERGE

130 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06290505 2026-05-08

PALEO

54 enrolled

Esophageal Neoplasms

NCT06564623 2026-05-08

Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)

25 enrolled

Diabetes Mellitus, Insulin-Dependent, 12, Biliary Tract Neoplasms, Carcinoma

NCT06728410 2026-05-08

A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement

38 enrolled

Cholangiocarcinoma

NCT01042379 2026-05-06

I-SPY

5,000 enrolled

BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT06441747 2026-05-06

Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP)

40 enrolled

Cholangiocarcinoma

NCT07195695 2026-05-06

Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

400 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07122089 2026-05-05

IOSPHERE

80 enrolled

Carcinoma, Hepatocellular

NCT04585490 2026-05-04

Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC

48 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05624996 2026-05-04

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

474 enrolled

Lung Neoplasms

NCT07166406 2026-05-04

Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial

226 enrolled

Carcinoma, Hepatocellular

NCT06103864 2026-04-30

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

625 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT06710223 2026-04-30

Cryoablation and Arterial Infusion of SD-101 in Combination With Durvalumab and Tremelimumab

20 enrolled

Carcinoma, Hepatocellular

NCT05903092 2026-04-29

MOZART

84 enrolled

Small Cell Lung Carcinoma

NCT06960577 2026-04-23

Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)

150 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT07339059 2026-04-23

Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

35 enrolled

Lung Neoplasms, Small Cell Lung Carcinoma

NCT05655949 2026-04-22

Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio

30 enrolled

Bile Duct Neoplasms, Cholangiocarcinoma

NCT06773910 2026-04-22

TIGOS-LS

250 enrolled

Limited Stage Small Cell Lung Cancer

NCT03942328 2026-04-20

Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer

85 enrolled

Carcinoma, Hepatocellular, Cholangiocarcinoma

NCT06780137 2026-04-20

MK-6070-002

262 enrolled

Small Cell Lung Carcinoma

NCT03317158 2026-04-15

ADAPT-BLADDER